Grand Rounds | Office of Correctional Medicine
Gabapentinoids in Correctional Healthcare:
Balancing Clinical Use, Risk Mitigation, and Deprescribing
Presented by the SIU School of Medicine Office of Correctional Medicine
WebEx Link
Password: SIU123
Beaux Cole, PharmD, RPh, CCHP
Dr. Cole serves as Director of Pharmaceutical Standards and Operations for the Office of Correctional Medicine at SIU School of Medicine. He’s been with SIU since 2019, focusing on clinical pharmacy programs and system-wide pharmacy operations. He’s currently working on statewide process improvements for IDOC.
Laura Knuf, PharmD, RPh, CCHP
Dr. Knuf is employed as a Pharmacy Operations Professional by the Office of Correctional Medicine at SIU School of Medicine. She has been with SIU since 2024 and has 14 years of practice experience in retail pharmacy. Her current focus is on evaluating medication management and administration processes within the Illinois Department of Corrections facilities, in an effort to develop and implement standardized policies.
Elizabeth Kunz, PharmD, RPh
Dr. Kunz is a Pharmacy Operations Professional for the Office of Correctional Medicine at SIU School of Medicine. She's been with SIU since 2024 and has worked in retail pharmacy for 18 years. Liz takes special interest in patient counseling and medication therapy management.
Brian Strader, PharmD, RPh
Dr. Strader works as a Pharmacy Operations Professional for the Office of Correctional Medicine at SIU School of Medicine. He has been with SIU since 2024 and has worked as clinical pharmacist for 19 years. Currently working to improve medication management process for IDOC.
Those participating in this activity will be able to:
- Identify appropriate and inappropriate prescribing practices for gabapentinoids in correctional healthcare settings to reduce misuse and optimize patient outcomes.
- Evaluate the risks associated with gabapentinoid use, including potential for misuse, dependence, and co-prescription with opioids, to make informed clinical decisions in patients that are incarcerated.
- Demonstrate evidence-based strategies for safely deprescribing gabapentinoids in correctional healthcare while ensuring effective pain management and minimizing withdrawal risks.
Disclosures:
None of the speakers, planners, or course directors have any relevant financial relationships with ineligible companies to disclose.
ACCREDITATION and CREDIT DESIGNATION:
Southern Illinois University (SIU) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
SIU School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
SIU School of Medicine is preapproved as a continuing nursing education provider pursuant to Section 1300.130, subsection c), 1), B) and P) of the Illinois Department of Financial and Professional Regulation Nurse Practice Act. Nurses may receive a maximum of 1.0 contact hour for completing this activity.
SIU School of Medicine has been approved by the Illinois Department of Financial and Professional Regulation as a provider of continuing education for social workers (license #159-000106), clinical psychologists (license # 268-000008), professional counselors/clinical counselors (license #197-000073), nursing home administrators (license # 199-000121), and dietitians/nutrition counselors (license # 199-000106). This program offers a maximum of 1.0 CE hour.
DISCLOSURE POLICY
It is the policy of Southern Illinois University School of Medicine that speakers, planners and anyone in control of content disclose real or apparent conflicts of interest relating to the topics of this activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The SIU School of Medicine Office of Continuing Professional Development has policies in place that will identify and mitigate all conflicts of interest prior to this activity. Detailed disclosure will be provided prior to the start of the activity.
